Establishing defined communities of Antarctic soil bacteria as potential sources of antimicrobials

The discovery of antibiotics is one of the greatest achievements in human medicine.

However, the introduction and overuse of antibiotics led towards selection of multidrug-resistant bacterial pathogens that are one of the major concerns of modern medicine. Novel antibiotic classes are the most promising way to overcome current antibiotic resistance.

To achieve this goal, antibacterial drug development is re-focused once again on natural products, especially by sourcing not-yet-explored or underexplored environments that represent a rich source of potentially bioactive microorganisms. One of such unique and intact environments is Antarctica with surprisingly high microbial biodiversity.

The Antarctic soil microbiome has been proven as a rich reservoir of biosynthetically active bacteria with potential to produce novel antimicrobial molecules.

However, simple exploration for antimicrobials among isolated microorganisms has its limitation, one of which is supressed expression of biosynthetic genes in laboratory conditions.

The aim of the proposed project is to search for antimicrobial metabolites among unique Antarctic isolates and to streamline the process through a novel approach.

Biosynthetic potential of isolates will be firstly characterized through genomics to identify the most promising strains.

Afterwards, a novel tool, co-cultivation combined with high advanced omics methods will be implemented to design and grow well-defined microbial communities.

Mutual microbial interactions in communities will stimulate metabolic activities of individual strains and expression of otherwise ‘silent’ genes resulting in production of various compounds, some of which may express antimicrobial activities.

This project will result in establishment of the first defined Antarctic microbiotas and access their full biosynthetic potential to produce bioactive compounds, especially those active against the most critical multidrug-resistant bacterial pathogens in human healthcare.